Миша Крашенинников

Mr. Миша Крашенинников

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
MRM. F. Rasulov
M. F. Rasulov
AVA. V. Vasil’cHenkov
A. V. Vasil’cHenkov
NON. A. Onishchenko
N. A. Onishchenko
МКМиша Крашенинников
Миша Крашенинников
VKV. I. Kravchenko
V. I. Kravchenko
IPI. V. Potapov
I. V. Potapov

13 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KKKonstantin V. Kokov
Konstantin V. Kokov
BEBayirta Egorova
Bayirta Egorova
MGMarina N. German
Marina N. German
Ilya D. KlabukovIlya D. Klabukov
Ilya D. Klabukov
МКМиша Крашенинников
Миша Крашенинников
DCDmitry Y. Chuvilin
Dmitry Y. Chuvilin
Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughter alpha-emitter short-lived 212Bi (T1/2 = 1 h), provides the possibility for the synthesis and purification of complex radiopharmaceuticals with minimum loss of radioactivity during preparation. As a benefit for clinical implementation, it can be milked from a radionuclide generator in different ways. The main approaches applied for these purposes are considered and described in this review, including chromatographic, solution, and other techniques to isolate 212Pb from its parent radionuclide. Furthermore, molecules used for lead’s binding and radiochemical features of preparation and stability of compounds labeled with 212Pb are discussed. The results of preclinical studies with an estimation of therapeutic and tolerant doses as well as recently initiated clinical trials of targeted radiopharmaceuticals are presented.

1 August 2003 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
VSV. I. Shumakov
V. I. Shumakov
NON. A. Onishchenko
N. A. Onishchenko
MRM. F. Rasulov
M. F. Rasulov
МКМиша Крашенинников
Миша Крашенинников
VZV. A. Zaidenov
V. A. Zaidenov

27 October 2018 in Molecules
Verified
Journal Article
Open access
PDF file
EREugene Rogozhin
Eugene Rogozhin
VSVera Sadykova
Vera Sadykova
ABAnna Baranova
Anna Baranova
Alexey VasilchenkoAlexey Vasilchenko
Alexey Vasilchenko
Vladislav LushpaVladislav Lushpa
Vladislav Lushpa
YAYaroslav A. Andreev
Yaroslav A. Andreev
Soil fungi are known to contain a rich variety of defense metabolites that allow them to compete with other organisms (fungi, bacteria, nematodes, and insects) and help them occupy more preferential areas at the expense of effective antagonism. These compounds possess antibiotic activity towards a wide range of other microbes, particularly fungi that belong to different taxonomical units. These compounds include peptaibols, which are non-ribosomal synthesized polypeptides containing non-standard amino acid residues (alpha-aminoisobutyric acid mandatory) and some posttranslational modifications. We isolated a novel antibiotic peptide from the culture medium of Emericellopsis alkalina, an alkalophilic strain. This peptide, called emericellipsin A, exhibited a strong antifungal effect against the yeast Candida albicans, the mold fungus Aspergillus niger, and human pathogen clinical isolates. It also exhibited antimicrobial activity against some Gram-positive and Gram-negative bacteria. Additionally, emericellipsin A showed a significant cytotoxic effect and was highly active against Hep G2 and HeLa tumor cell lines. We used NMR spectroscopy to reveal that this peptaibol is nine amino acid residues long and contains non-standard amino acids. The mode of molecular action of emericellipsin A is most likely associated with its effects on the membranes of cells. Emericellipsin A is rather short peptaibol and could be useful for the development of antifungal, antibacterial, or anti-tumor remedies.

5 October 2024 in Journal of Molecular Pathology
Verified
Journal Article
Open access
PDF file
Ilya D. KlabukovIlya D. Klabukov
Ilya D. Klabukov
ASAnna Smirnova
Anna Smirnova
AYAnna Yakimova
Anna Yakimova
AKAlexander E. Kabakov
Alexander E. Kabakov
DADmitrii Atiakshin
Dmitrii Atiakshin
AKAndrei Kaprin
Andrei Kaprin
The extracellular matrix is an organized three-dimensional network of protein-based molecules and other macromolecules that provide structural and biochemical support to tissues. Depending on its biochemical and structural properties, the extracellular matrix influences cell adhesion and signal transduction and, in general, can influence cell differentiation and proliferation through specific mechanisms of chemical and mechanical sensing. The development of body tissues during ontogenesis is accompanied by changes not only in cells but also in the composition and properties of the extracellular matrix. Similarly, tumor development in carcinogenesis is accompanied by a continuous change in the properties of the extracellular matrix of tumor cells, called ‘oncomatrix’, as the tumor matures, from the development of the primary focus to the stage of metastasis. In this paper, the characteristics of the composition and properties of the extracellular matrix of tumor tissues are considered, as well as changes to the composition and properties of the matrix during the evolution of the tumor and metastasis. The extracellular matrix patterns of tumor tissues can be used as biomarkers of oncological diseases as well as potential targets for promising anti-tumor therapies.

1 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Ilya D. KlabukovIlya D. Klabukov
Ilya D. Klabukov
TTTimur Tenchurin
Timur Tenchurin
ASAlexey Shepelev
Alexey Shepelev
DBDenis Baranovskii
Denis Baranovskii
VMVissarion Mamagulashvili
Vissarion Mamagulashvili
SCSergei N. Chvalun
Sergei N. Chvalun
This article reports the electrospinning technique for the manufacturing of multilayered scaffolds for bile duct tissue engineering based on an inner layer of polycaprolactone (PCL) and an outer layer either of a copolymer of D,L-lactide and glycolide (PLGA) or a copolymer of L-lactide and ε-caprolactone (PLCL). A study of the degradation properties of separate polymers showed that flat PCL samples exhibited the highest resistance to hydrolysis in comparison with PLGA and PLCL. Irrespective of the liquid-phase nature, no significant mass loss of PCL samples was found in 140 days of incubation. The PLCL- and PLGA-based flat samples were more prone to hydrolysis within the same period of time, which was confirmed by the increased loss of mass and a significant reduction of weight-average molecular mass. The study of the mechanical properties of developed multi-layered tubular scaffolds revealed that their strength in the longitudinal and transverse directions was comparable with the values measured for a decellularized bile duct. The strength of three-layered scaffolds declined significantly because of the active degradation of the outer layer made of PLGA. The strength of scaffolds with the PLCL outer layer deteriorated much less with time, both in the axial (p-value = 0.0016) and radial (p-value = 0.0022) directions. A novel method for assessment of the physiological relevance of synthetic scaffolds was developed and named the phase space approach for assessment of physiological relevance. Two-dimensional phase space (elongation modulus and tensile strength) was used for the assessment and visualization of the physiological relevance of scaffolds for bile duct bioengineering. In conclusion, the design of scaffolds for the creation of physiologically relevant tissue-engineered bile ducts should be based not only on biodegradation properties but also on the biomechanical time-related behavior of various compositions of polymers and copolymers.